Evolus (NASDAQ:EOLS – Get Free Report) and Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Evolus and Gyre Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
| Gyre Therapeutics | 1 | 1 | 0 | 0 | 1.50 |
Evolus presently has a consensus target price of $14.50, suggesting a potential upside of 103.71%. Given Evolus’ stronger consensus rating and higher probable upside, equities analysts clearly believe Evolus is more favorable than Gyre Therapeutics.
Valuation & Earnings
This table compares Evolus and Gyre Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evolus | $297.18 million | 1.58 | -$51.64 million | ($0.52) | -13.69 |
| Gyre Therapeutics | $116.59 million | 5.81 | $5.03 million | ($0.21) | -28.95 |
Gyre Therapeutics has lower revenue, but higher earnings than Evolus. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
90.7% of Evolus shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 5.0% of Evolus shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Evolus and Gyre Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evolus | -10.85% | N/A | -13.00% |
| Gyre Therapeutics | -15.47% | -6.57% | -5.35% |
Risk & Volatility
Evolus has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500.
Summary
Evolus beats Gyre Therapeutics on 8 of the 14 factors compared between the two stocks.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
About Gyre Therapeutics
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
